search
Back to results

Safety, and Tolerability of the ZENS Device (PLUTO)

Primary Purpose

Snoring, Obstructive Sleep Apnea

Status
Completed
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
ZENS
Sponsored by
Zennea Technologies Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Snoring focused on measuring Sleep Apnea, Snoring

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion:

  1. Adult (age of majority).
  2. Willing and able to provide written informed consent.
  3. BMI <35.
  4. Neck circumference <18 inches.
  5. History of disruptive snoring for most of the night, 12 or more of the last 14 nights.
  6. Level 3 at-home sleep test (Sagatech SnoreSat Sleep Recorder, Philips Alice OneNight or equivalent) recording from the past 12 months (prior to enrolment) with more than 4 hours of both oximetry and flow data for review; or willing to undergo a level 3 sleep test prior to overnight in-laboratory polysomnography assessment. The respiratory disturbance index (RDI) must be <15events/hour.
  7. Ability and willingness to shave significant facial hair (i.e. be clean shaven) for the overnight visit; and to cease wearing cosmetic products and/or moisturizing cream and/or remove excessive oil in the chin / jaw region (i.e. be clean skinned) for the overnight visit; and to wear clothing that covers the chest (e.g. a t-shirt) for the duration of the overnight visit.
  8. Willing to participate in overnight portion of study without use of another snoring/OSA treatment (CPAP, oral appliance) in the 72 hours prior to the overnight visit.
  9. Willing to refrain from use of alcohol, sedative hypnotics, or recreational drugs for 24 hours prior to and during the study.

Exclusion:

  1. Prior diagnosis of moderate or severe OSA (AASM defines OSA severity as: Mild=AHI ≥5 and <15; Moderate=AHI ≥15 and <30; Severe = ≥30/hour).
  2. Known sleep disturbance other than snoring (insomnia, parasomnia, narcolepsy, restless legs syndrome, circadian rhythm disorder, or other disorder likely to interfere with the study).
  3. Fixed anatomical abnormality of the upper airway (e.g. history of head or neck trauma, head and neck malignancy, previous tracheotomy, subglottic stenosis, deformed uvula, aglossia) from trauma, malignancy, prior surgery, or congenital condition.
  4. Individuals with a history of severe nasal obstruction due to anatomical problems such as deviated septum, previously broken nose or non-anatomical factors such as chronic rhinitis or nasal polyposis.
  5. Enflamed/enlarged tonsils.
  6. Use of another snoring treatment (CPAP, medication or oral appliance) in the 72 hours prior to the overnight visit.
  7. Anatomic neck or skin abnormalities likely to interfere with fixation of the ZENS Device.
  8. Presence of an implantable medical device susceptible to electrical interference (e.g. pacemaker or defibrillator).
  9. History of epilepsy.
  10. Use of sedatives, hypnotics, recreational drug or alcohol in the 24 hours prior to the study.
  11. Known allergy to medical tape.
  12. Any severe skin condition affecting the head and neck likely to be aggravated by adhesives (e.g. psoriasis, eczema).
  13. Recent surgery to the face or neck (i.e. within the past 5 years).
  14. Inability to wear something on the neck or tolerate PSG procedure.
  15. Pregnancy.
  16. Any other criteria, which would make the participant unsuitable to participate in this study as determined by the site Principal Investigator (e.g. uncontrolled drug and/or alcohol addiction, extreme frailty, comorbidities, ongoing medication regimen, cognitive ability to follow instructions, etc.).

Sites / Locations

  • University of Calgary, FMC Sleep Centre
  • Tranq Sleep Centre

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Sequence 1

Sequence 2

Arm Description

Participants allocated to Sequence 1 will complete the overnight sleep study with the ZENS device "ON" for the first half and "OFF" for the second half.

Participants allocated to Sequence 1 will complete the overnight sleep study with the ZENS device "OFF" for the first half and "ON" for the second half

Outcomes

Primary Outcome Measures

Percent change in loud snoring time
The percentage change in snoring time in the "ON" versus "OFF" period

Secondary Outcome Measures

Change in AHI
Change in AHI in the "ON" versus "OFF" period
Percentage difference of time (minutes) per hour of sleep with loud snoring
Percentage difference of time (minutes) per hour of sleep with loud snoring (≥40) in the "ON" versus "OFF" phase
Change in the number of arousals and awakenings in the "ON" versus "OFF" phase
Change in the number of arousals and awakenings in the "ON" versus "OFF" phase
Difference in the mean oxygen saturation levels
Difference in the mean oxygen saturation levels in the "ON" versus "OFF" phase
Number of patients with successful snoring reduction
≥ 25% reduction in snoring intensity in the "OFF" versus the "ON" period.

Full Information

First Posted
August 19, 2019
Last Updated
June 23, 2021
Sponsor
Zennea Technologies Inc.
Collaborators
University of Calgary, Interior Health
search

1. Study Identification

Unique Protocol Identification Number
NCT04063917
Brief Title
Safety, and Tolerability of the ZENS Device (PLUTO)
Official Title
An Initial Investigation of the Safety and Tolerability of Transcutaneous Stimulation of the Hypoglossal Nerve for the Treatment of Primary Snoring and Mild Sleep Apnea Using the ZENS Transcutaneous Nerve Stimulator (PLUTO)
Study Type
Interventional

2. Study Status

Record Verification Date
June 2021
Overall Recruitment Status
Completed
Study Start Date
November 1, 2019 (Actual)
Primary Completion Date
April 1, 2021 (Actual)
Study Completion Date
June 18, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Zennea Technologies Inc.
Collaborators
University of Calgary, Interior Health

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The primary objective of the PLUTO study is to evaluate the safety and tolerability of the ZENS transcutaneous nerve stimulator device in primary snorers and those with mild obstructive sleep apnea. The study will assess the impact of ZENS on snoring frequency, duration, and other relevant sleep parameters. The intended purpose of the investigational device is to deliver a transcutaneous electrical stimulation signal to the hypoglossal nerve in the "ON" phase in order to alter the apnea hypopnea index (AHI), as well as mean snoring burden (intensity, duration), and to deliver no signal in the "OFF" phase of the study as a means for comparison. Subjects utilizing the ZENS Device will experience a reduction in snoring during the "ON" versus "OFF" phase, as quantified by a reduction in the percentage of time per hour of snoring (≥40 dB) in the active ZENS Device ("ON" phase) versus the inactive ZENS Device ("OFF" phase).
Detailed Description
After indicating their consent to contact and signing an Informed Consent Form, potential participants will undergo a screening assessment that includes a review of their medical history, a focused physical exam, and a level 3 at-home sleep test (Sagatech SnoreSat Sleep Recorder, Philips Alice OneNight or equivalent), if not already available in the medical records). At the screening visit potential participants' eligibility for the study will be evaluated against the study inclusion and exclusion criteria. Following confirmation of eligibility, up to 45 (n=45) participants will be scheduled for their overnight in-laboratory PSG, which must occur no more than 12 weeks after screening has taken place. A final determination of eligibility and "enrollment" is completed when inclusion and exclusion criteria are verified on the day of the study visit. Those who do not meet inclusion and exclusion criteria on the day of the study will be deemed "screening failures". Participants will wear the ZENS Device for the 8 to 12-hour overnight in-laboratory polysomnography assessment. Participants will be monitored for and asked about any adverse events and device effects that they experience during the overnight sleep study. Participants will be contacted by the site via telephone 24 to 96 hours after the overnight sleep study to determine if any adverse events and device effects were experienced late after the overnight polysomnography. After the telephone follow-up, participation in the study is complete.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Snoring, Obstructive Sleep Apnea
Keywords
Sleep Apnea, Snoring

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Multi-center, open label randomized 2x2 cross-over sleep study of the ZENS transcutaneous hypoglossal nerve stimulator in the "ON" (active) versus "OFF" (passive) setting during a single over-night sleep study.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
45 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sequence 1
Arm Type
Experimental
Arm Description
Participants allocated to Sequence 1 will complete the overnight sleep study with the ZENS device "ON" for the first half and "OFF" for the second half.
Arm Title
Sequence 2
Arm Type
Experimental
Arm Description
Participants allocated to Sequence 1 will complete the overnight sleep study with the ZENS device "OFF" for the first half and "ON" for the second half
Intervention Type
Device
Intervention Name(s)
ZENS
Intervention Description
ZENS transcutaneous nerve stimulator (ZENS Device), a wearable and non-invasive device which stimulates nerves in the neck to reduce airway obstruction and maintain muscular tension while sleeping to reduce snoring severity.
Primary Outcome Measure Information:
Title
Percent change in loud snoring time
Description
The percentage change in snoring time in the "ON" versus "OFF" period
Time Frame
up to 5 hours
Secondary Outcome Measure Information:
Title
Change in AHI
Description
Change in AHI in the "ON" versus "OFF" period
Time Frame
up to 5 hours
Title
Percentage difference of time (minutes) per hour of sleep with loud snoring
Description
Percentage difference of time (minutes) per hour of sleep with loud snoring (≥40) in the "ON" versus "OFF" phase
Time Frame
up to 5 hours
Title
Change in the number of arousals and awakenings in the "ON" versus "OFF" phase
Description
Change in the number of arousals and awakenings in the "ON" versus "OFF" phase
Time Frame
up to 5 hours
Title
Difference in the mean oxygen saturation levels
Description
Difference in the mean oxygen saturation levels in the "ON" versus "OFF" phase
Time Frame
up to 5 hours
Title
Number of patients with successful snoring reduction
Description
≥ 25% reduction in snoring intensity in the "OFF" versus the "ON" period.
Time Frame
up to 5 hours
Other Pre-specified Outcome Measures:
Title
Incidence of adverse events, serious adverse events, device deficiencies and unanticipated adverse device effects
Description
Safety and tolerability of intervention
Time Frame
up to 96 hours
Title
Percent of the time the ZENS Device was adhered to the participant
Description
% time worn during entire study (awake and asleep)
Time Frame
up to 12 hours
Title
Tolerability of the ZENS Device
Description
% of time worn during sleep
Time Frame
up to 12 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion: Adult (age of majority). Willing and able to provide written informed consent. BMI <35. Neck circumference <18 inches. History of disruptive snoring for most of the night, 12 or more of the last 14 nights. Level 3 at-home sleep test (Sagatech SnoreSat Sleep Recorder, Philips Alice OneNight or equivalent) recording from the past 12 months (prior to enrolment) with more than 4 hours of both oximetry and flow data for review; or willing to undergo a level 3 sleep test prior to overnight in-laboratory polysomnography assessment. The respiratory disturbance index (RDI) must be <15events/hour. Ability and willingness to shave significant facial hair (i.e. be clean shaven) for the overnight visit; and to cease wearing cosmetic products and/or moisturizing cream and/or remove excessive oil in the chin / jaw region (i.e. be clean skinned) for the overnight visit; and to wear clothing that covers the chest (e.g. a t-shirt) for the duration of the overnight visit. Willing to participate in overnight portion of study without use of another snoring/OSA treatment (CPAP, oral appliance) in the 72 hours prior to the overnight visit. Willing to refrain from use of alcohol, sedative hypnotics, or recreational drugs for 24 hours prior to and during the study. Exclusion: Prior diagnosis of moderate or severe OSA (AASM defines OSA severity as: Mild=AHI ≥5 and <15; Moderate=AHI ≥15 and <30; Severe = ≥30/hour). Known sleep disturbance other than snoring (insomnia, parasomnia, narcolepsy, restless legs syndrome, circadian rhythm disorder, or other disorder likely to interfere with the study). Fixed anatomical abnormality of the upper airway (e.g. history of head or neck trauma, head and neck malignancy, previous tracheotomy, subglottic stenosis, deformed uvula, aglossia) from trauma, malignancy, prior surgery, or congenital condition. Individuals with a history of severe nasal obstruction due to anatomical problems such as deviated septum, previously broken nose or non-anatomical factors such as chronic rhinitis or nasal polyposis. Enflamed/enlarged tonsils. Use of another snoring treatment (CPAP, medication or oral appliance) in the 72 hours prior to the overnight visit. Anatomic neck or skin abnormalities likely to interfere with fixation of the ZENS Device. Presence of an implantable medical device susceptible to electrical interference (e.g. pacemaker or defibrillator). History of epilepsy. Use of sedatives, hypnotics, recreational drug or alcohol in the 24 hours prior to the study. Known allergy to medical tape. Any severe skin condition affecting the head and neck likely to be aggravated by adhesives (e.g. psoriasis, eczema). Recent surgery to the face or neck (i.e. within the past 5 years). Inability to wear something on the neck or tolerate PSG procedure. Pregnancy. Any other criteria, which would make the participant unsuitable to participate in this study as determined by the site Principal Investigator (e.g. uncontrolled drug and/or alcohol addiction, extreme frailty, comorbidities, ongoing medication regimen, cognitive ability to follow instructions, etc.).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marcus Povitz, MD
Organizational Affiliation
University of Calgary
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Calgary, FMC Sleep Centre
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T2N 4N1
Country
Canada
Facility Name
Tranq Sleep Centre
City
Cranbrook
State/Province
British Columbia
ZIP/Postal Code
V1C 3W3
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No
Links:
URL
http://www.zenneatech.com/
Description
Zennea Technologies website

Learn more about this trial

Safety, and Tolerability of the ZENS Device (PLUTO)

We'll reach out to this number within 24 hrs